Track market-moving stories before they get noisy

AbbVie (ABBV +0.84%) was spun off from Abbott (ABT +2.29%) in 2013. That's an important fact to keep in mind when you look at AbbVie's Dividend King status. Technically, it hasn't increased its dividend annually for 50 years because it hasn't existed as a stand-alone company for 50 years. But don't let that fact dissuade you from looking at this much-loved dividend stock. Here's what you need to know.

Carrying the Dividend King mantle While AbbVie inherited its status as a Dividend King from its former parent, Abbott, it has increased its dividend every year since the spin-off. It is clear that AbbVie understands how important dividends are to its shareholders.

Image source: Getty Images.

Meanwhile, today's yield is quite attractive at 2.7%. For comparison, the S&P 500 Index's (^GSPC +0.05%) yield is only around 1%, and the average pharmaceutical stock's yield is just 1.5%. The problem is that the payout ratio is a shockingly high 330% right now. But that's not necessarily the best gauge here.

AbbVie generates high, recurring cash flows from drug sales. Since dividends are paid from cash flow, the earnings picture isn't a complete view of a company's dividend-paying ability. Looking at cash flows, AbbVie's cash dividend payout ratio is around 60%. That suggests the dividend is on much firmer ground than it appears to dividend investors at first. Meanwhile, the balance sheet is investment-grade rated, so the company is financially strong.

What about AbbVie's drug business? AbbVie has a strong foundation in immunology and oncology. Through acquisitions, it has entered the aesthetics and neuroscience spaces, while bolstering its oncology position. Immunology is an interesting example of the company's drug pipeline.

Humira was a blockbuster drug for AbbVie, but like all drugs, it eventually lost patent protection. When that happens, revenues usually fall as generic versions of the drug enter the market. However, AbbVie introduced Skyrizi and Rinvoq, which appear to be more effective than Humira. That has helped to soften the hit from Humira's patent expiration.

Notably, AbbVie recently agreed to buy Apogee (APGE +0.01%) for roughly $11 billion. According to AbbVie, the deal will bring with it "multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis (AD) and asthma." Essentially, this transaction builds on the company's strengths and positions it well for the future. That's exactly what the company achieved with previous acquisitions, including Allergan, Cerevel, and ImmunoGen.

Today's Change

(

0.84

%) $

2.16

Current Price

$

259.08

But there's another nuance hidden in the portfolio, as well. The company makes Botox, a drug whose patent protection has expired. However, this drug falls into the aesthetics category, where brand names are much more important. So, it remains a very profitable source of revenue for the company and will likely remain so for years to come. That's a foundation that most pharmaceutical companies don't have. Botox, meanwhile, is also finding healthcare uses, including its approved treatment of migraines, and is being used off-label in other areas, such as erectile dysfunction, which could lead to approved uses down the line.

When you step back and look at the big picture, AbbVie has a proven track record of developing valuable drugs. It has a proven track record of acquiring companies with attractive drug candidates. And it has an underlying foundation in Botox that differentiates it from its peers.

AbbVie: A worthwhile long-term dividend holding As a spin-off, AbbVie may not have earned its place on the Dividend King list. But it has certainly proven it deserves to stay on the list. Given the attractive yield, it's little wonder why Wall Street can't get enough of this high-yield drug maker. If you are a long-term dividend investor, you might want to get in on the action, too.

The market expects AbbVie (ABBV - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 31. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis drugmaker is expected to post quarterly earnings of $3.66 per share in its upcoming report, which represents a year-over-year change of +23.2%.

Revenues are expected to be $16.81 billion, up 9% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.11% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for AbbVie?For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -1.01%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that AbbVie will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that AbbVie would post earnings of $2.62 per share when it actually produced earnings of $2.65, delivering a surprise of +1.15%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

AbbVie doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

One basis point separates these two healthcare funds. Here is why the bigger decision is whether to own healthcare at all.

With the stock market trading sideways since the start of summer, concerns are running high about a possible near-term downturn. Rather than exiting the market, consider leaning into defensive names.

Blue chip dividend stocks are a prime example. These durable, high-quality businesses provide steady cash payouts each quarter, all while leaving the door open for long-term price appreciation.

Among dividend stocks in this category, a few stand out as strong opportunities right now: AbbVie (ABBV +1.40%), Chevron (CVX +1.76%), and PepsiCo (PEP -0.55%).

Image source: Getty Images.

AbbVie's comeback points to further dividend growth Pharmaceutical company AbbVie has raised its dividend annually since being spun off from Abbott Laboratories in 2013. A few years ago, the company entered a rough patch due to the then-pending expiration of patent exclusivity for its Humira anti-inflammatory treatment.

However, thanks to the success of immunology therapies like Skyrizi and Rinvoq, AbbVie has experienced a rebound. Sales growth and operating income have bounced back. After making a further pivot toward immunology, through its pending acquisition of Apogee Therapeutics, AbbVie appears well-positioned for further earnings growth. Forecasts call for revenue and earnings growth of around 10% and 40%, respectively, during 2026.

Today's Change

(

1.40

%) $

3.55

Current Price

$

256.85

As earnings growth continues, AbbVie remains well-positioned to continue its dividend growth streak. Currently, the stock has a forward dividend yield of around 2.75%, with annual dividend growth averaging nearly 6% over the past five years.

Chevron remains a Dividend King in the making Integrated oil and gas company Chevron has nearly 40 years of consecutive dividend growth. That means it's just a little over a decade away from attaining Dividend King status. Dividend Kings are stocks with 50 or more years of consecutive dividend growth.

With a forward dividend yield of around 3.75%, Chevron has also raised its dividend by an average of 6% over the past five years. An additional wave of mid-single-digit dividend growth may be in the cards. Even as crude oil prices have eased since the geopolitically driven supply shocks earlier this year, they remain within a range that supports the energy company's long-term cash flow growth goals.

Today's Change

(

1.76

%) $

3.40

Current Price

$

196.38

As announced last November, Chevron's game plan to "maintain capital and cost discipline" could lead to 10% annualized earnings growth between now and 2030 if Brent crude oil prices stay above $70 per barrel. Alongside cost-cutting measures, Chevron's game plan also entails leaning into growth opportunities, such as providing power solutions for artificial intelligence (AI) data centers.

PepsiCo: A contrarian buy among dividend stocks PepsiCo shares have fallen out of favor in recent months. The packaged food and beverage company continues to struggle with declining U.S. market share, even as quarterly results beat forecasts.

Yet while the market remained bearish, much suggests ample rewards for those going contrarian at present price levels. Right now, the stock has a forward dividend yield of around 4.4%. PepsiCo is already a Dividend King, with a 54-year track record of annual dividend increases, and the company's dividend growth has averaged around 6% annually over the past five years.

Today's Change

(

-0.55

%) $

-0.75

Current Price

$

134.90

As Morgan Stanley's Dara Mohsenian recently noted, factors like tariff refunds and continued strong international results could help offset recent concerns. Since PepsiCo's shares are trading for only 18 times forward earnings, while competitor Coca-Cola trades for 25 times forward earnings, there's ample upside potential if sentiment improves.

Posted by Defense World Staff on Jul 23rd, 2026

Ascension Capital Advisors Inc. bought a new position in AbbVie Inc. (NYSE:ABBV – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 4,373 shares of the company’s stock, valued at approximately $951,000. AbbVie comprises about 0.3% of Ascension Capital Advisors Inc.’s holdings, making the stock its 29th biggest position.

Several other hedge funds and other institutional investors have also recently modified their holdings of ABBV. Litman Gregory Wealth Management LLC purchased a new position in AbbVie in the fourth quarter worth about $28,000. Westend Capital Management LLC bought a new position in AbbVie in the fourth quarter worth approximately $29,000. Imprint Wealth LLC boosted its stake in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares during the last quarter. Legacy Wealth Managment LLC ID boosted its stake in shares of AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new position in AbbVie in the 4th quarter worth $31,000. 70.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In A number of analysts have recently issued reports on the stock. Citigroup increased their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Bank of America raised their price target on AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a report on Friday, July 10th. Cantor Fitzgerald boosted their price target on AbbVie from $240.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, July 6th. JPMorgan Chase & Co. upped their price target on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Monday, June 8th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $268.10.

Check Out Our Latest Stock Report on AbbVie

Key AbbVie News Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Canaccord Genuity raised its price target on AbbVie to $282 from $273 and reiterated a buy rating, signaling confidence in further upside for AbbVie Inc. (ABBV). Benzinga report Positive Sentiment: AbbVie’s aesthetics business got a boost after Allergan Aesthetics received European Commission approval for Boey, expanding the company’s portfolio in Europe and potentially supporting future revenue growth. Yahoo Finance article Neutral Sentiment: Several recent articles characterized AbbVie as a strong buy-and-hold name and noted that the stock has recently outperformed the broader market, reinforcing a generally constructive long-term view. Yahoo Finance article Negative Sentiment: Investors are watching AbbVie’s Q2 oncology revenue closely, with analysts warning that weakness in Imbruvica may outweigh gains from Venclexta and newer cancer treatments, which could pressure results. Yahoo Finance article AbbVie Price Performance NYSE ABBV opened at $253.75 on Thursday. The stock has a market capitalization of $448.32 billion, a PE ratio of 125.00, a P/E/G ratio of 0.85 and a beta of 0.30. AbbVie Inc. has a 1-year low of $186.77 and a 1-year high of $261.64. The business has a 50 day simple moving average of $232.69 and a two-hundred day simple moving average of $222.41.

AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period last year, the firm posted $2.46 earnings per share. AbbVie’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, analysts anticipate that AbbVie Inc. will post 14.18 EPS for the current fiscal year.

AbbVie Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is currently 340.89%.

About AbbVie (Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

Read More Five stocks we like better than AbbVie Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAureus Asset Management LLC Decreases Stock Holdings in Johnson & Johnson $JNJ

NEXT HEADLINE »Assetmark Inc. Lowers Stake in The Allstate Corporation $ALL

Posted by Defense World Staff on Jul 22nd, 2026

ABN Amro Investment Solutions boosted its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 80.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 237,318 shares of the company’s stock after buying an additional 105,906 shares during the period. ABN Amro Investment Solutions’ holdings in AbbVie were worth $51,614,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie during the 4th quarter valued at $28,000. Imprint Wealth LLC lifted its position in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares during the period. Westend Capital Management LLC purchased a new position in AbbVie during the 4th quarter valued at about $29,000. IFC & Insurance Marketing Inc. bought a new stake in AbbVie during the fourth quarter worth about $31,000. Finally, Legacy Wealth Managment LLC ID grew its holdings in AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after purchasing an additional 73 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 1.1% AbbVie stock opened at $256.18 on Wednesday. The company has a market cap of $452.62 billion, a price-to-earnings ratio of 126.20, a PEG ratio of 0.84 and a beta of 0.30. The firm’s fifty day moving average is $231.78 and its 200 day moving average is $222.23. AbbVie Inc. has a 52-week low of $184.90 and a 52-week high of $261.64.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same period last year, the company posted $2.46 EPS. The business’s revenue was up 12.4% on a year-over-year basis. On average, equities research analysts anticipate that AbbVie Inc. will post 14.18 earnings per share for the current fiscal year.

AbbVie Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is currently 340.89%.

Trending Headlines about AbbVie Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie’s stock has been outperforming the broader market, with recent trading strength reinforcing investor confidence in the name. AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know Positive Sentiment: Analysts at Erste Group Bank reportedly raised earnings estimates for AbbVie, which can support the shares if investors expect stronger profit growth ahead. Erste Group Bank Brokers Boost Earnings Estimates for AbbVie Positive Sentiment: AbbVie said its ABBV-8736 injection study showed “quiet but meaningful” pipeline progress, adding another sign that its drug development efforts are advancing. AbbVie’s ABBV-8736 Injection Study Signals Quiet But Meaningful Pipeline Progress Positive Sentiment: A recent bullish article argued AbbVie looks like a strong buy-and-hold candidate, reflecting generally constructive sentiment around the stock. 3 Reasons to Buy AbbVie Stock Like There’s No Tomorrow Neutral Sentiment: A separate article discussed broader biotech and healthcare market trends, but it does not appear to have a direct company-specific impact on AbbVie. Biotech IPOs Surge 55% as AI Listings Lose Momentum Neutral Sentiment: Another article questioned whether AbbVie is leaving eye care, but the available headline alone does not indicate a clear financial impact. BLOG: Exit stage left: Is AbbVie leaving eye care? Neutral Sentiment: Coverage of AbbVie’s $10.9 billion Apogee acquisition focused on potential dividend effects, but the headline suggests investors are mainly evaluating the deal rather than reacting to a fresh negative catalyst. How Will AbbVie’s $10.9 Billion Acquisition of Apogee Impact Its Dividend? Wall Street Analyst Weigh In Several equities analysts have recently issued reports on ABBV shares. Wells Fargo & Company lifted their target price on shares of AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a report on Friday, July 10th. JPMorgan Chase & Co. raised their price objective on AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. UBS Group raised their price target on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Monday, July 13th. Finally, Evercore set a $235.00 price objective on shares of AbbVie in a research note on Friday, May 15th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $267.67.

View Our Latest Stock Analysis on AbbVie

AbbVie Company Profile (Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

See Also Five stocks we like better than AbbVie Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEABN Amro Investment Solutions Has $44.29 Million Stake in Xylem Inc. $XYL

NEXT HEADLINE »108,847 Shares in iShares U.S. Treasury Bond ETF $GOVT Purchased by a16z Perennial Management L.P.

Posted by Defense World Staff on Jul 21st, 2026

Baader Bank Aktiengesellschaft grew its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 560.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,380 shares of the company’s stock after buying an additional 6,263 shares during the period. Baader Bank Aktiengesellschaft’s holdings in AbbVie were worth $1,588,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in AbbVie by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after acquiring an additional 3,032,438 shares during the last quarter. State Street Corp boosted its holdings in shares of AbbVie by 1.4% during the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock worth $18,494,193,000 after acquiring an additional 1,119,274 shares during the period. Geode Capital Management LLC grew its position in shares of AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after purchasing an additional 4,190,487 shares during the last quarter. Bank of America Corp DE increased its stake in shares of AbbVie by 1.4% during the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock worth $5,900,617,000 after purchasing an additional 356,394 shares during the period. Finally, Norges Bank acquired a new stake in AbbVie during the 4th quarter worth approximately $5,865,055,000. 70.23% of the stock is currently owned by institutional investors.

Trending Headlines about AbbVie Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie reported quiet but meaningful pipeline progress in its ABBV-8736 injection study, which could support longer-term growth expectations if the program continues to advance. AbbVie’s ABBV-8736 Injection Study Signals Quiet But Meaningful Pipeline Progress Positive Sentiment: Some coverage says AbbVie should be able to preserve its dividend even after the $10.9 billion Apogee acquisition because the deal is being funded with debt rather than cash, reducing immediate pressure on reserves. How Will AbbVie’s $10.9 Billion Acquisition of Apogee Impact Its Dividend? Neutral Sentiment: Broker coverage and article commentary pointed to higher earnings estimates for AbbVie, but also noted the stock may be stretched versus its growth outlook, leaving the market split on whether upside is already priced in. Erste Group Bank Brokers Boost Earnings Estimates for AbbVie Neutral Sentiment: Broader pharma commentary placed AbbVie alongside other large drugmakers and suggested it has outperformed the S&P 500, but also described its valuation as relatively elevated compared with growth expectations. 3 Biggest Pharma Giants: Buy, Sell or Hold? Negative Sentiment: Some market commentary around AbbVie’s eye-care exposure raised questions about whether the company is pulling back from that segment, which could signal strategic uncertainty for part of its portfolio. BLOG: Exit stage left: Is AbbVie leaving eye care? Analyst Upgrades and Downgrades ABBV has been the subject of several recent research reports. Wells Fargo & Company boosted their price target on AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, July 10th. JPMorgan Chase & Co. raised their price target on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. BMO Capital Markets boosted their price objective on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Finally, Royal Bank Of Canada increased their target price on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $267.67.

View Our Latest Research Report on ABBV

AbbVie Trading Down 0.4% Shares of AbbVie stock opened at $253.37 on Tuesday. The firm’s 50 day moving average is $230.81 and its 200 day moving average is $222.04. The firm has a market capitalization of $447.66 billion, a PE ratio of 124.81, a price-to-earnings-growth ratio of 0.84 and a beta of 0.30. AbbVie Inc. has a 1 year low of $184.63 and a 1 year high of $261.64.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the prior year, the firm earned $2.46 EPS. The firm’s revenue was up 12.4% compared to the same quarter last year. As a group, research analysts anticipate that AbbVie Inc. will post 14.18 earnings per share for the current year.

AbbVie Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

AbbVie Company Profile (Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

Read More Five stocks we like better than AbbVie The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEWestern Digital Corporation $WDC Shares Bought by Baader Bank Aktiengesellschaft

Posted by Defense World Staff on Jul 20th, 2026

Dimensional Fund Advisors LP lowered its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 10.5% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,411,238 shares of the company’s stock after selling 868,264 shares during the period. AbbVie accounts for about 0.3% of Dimensional Fund Advisors LP’s holdings, making the stock its 29th largest holding. Dimensional Fund Advisors LP owned 0.42% of AbbVie worth $1,611,690,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ABBV. Litman Gregory Wealth Management LLC purchased a new stake in shares of AbbVie in the fourth quarter worth $28,000. Westend Capital Management LLC purchased a new position in shares of AbbVie in the 4th quarter worth about $29,000. Imprint Wealth LLC raised its position in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the last quarter. Legacy Wealth Managment LLC ID boosted its stake in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after purchasing an additional 73 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. purchased a new stake in AbbVie during the 4th quarter valued at about $31,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 0.0% Shares of NYSE ABBV opened at $254.53 on Monday. The firm’s 50-day moving average price is $229.80 and its 200-day moving average price is $221.87. AbbVie Inc. has a 52-week low of $184.63 and a 52-week high of $261.64. The company has a market cap of $449.70 billion, a PE ratio of 125.38, a PEG ratio of 0.84 and a beta of 0.30.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.46 earnings per share. As a group, equities research analysts anticipate that AbbVie Inc. will post 14.18 EPS for the current fiscal year.

AbbVie Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s payout ratio is currently 340.89%.

Analyst Ratings Changes Several research analysts have issued reports on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $298.00 target price on shares of AbbVie in a report on Tuesday, June 23rd. Wells Fargo & Company raised their price target on shares of AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, July 10th. HSBC restated a “buy” rating and issued a $300.00 price objective on shares of AbbVie in a report on Monday, July 6th. UBS Group upped their price objective on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Monday, July 13th. Finally, Canaccord Genuity Group increased their target price on AbbVie from $265.00 to $273.00 and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $267.67.

Read Our Latest Stock Report on ABBV

Key AbbVie News Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie’s Allergan Aesthetics unit won European Commission approval for Boey® (trenibotulinumtoxinE), a new facial injectable for glabellar lines. The approval gives AbbVie a differentiated aesthetics product in all 30 EEA countries and could add another growth driver to offset Humira-related declines. Article Title Positive Sentiment: Investors are also focusing on AbbVie’s neuroscience franchise and other newer product catalysts, with analysts expecting solid Q2 growth and continued momentum from brands such as Vyalev, RINVOQ, and SKYRIZI ahead of earnings. Article Title Positive Sentiment: Brokerage sentiment remains constructive, with recent coverage showing a “Moderate Buy” consensus and multiple price-target increases in July, reinforcing confidence in AbbVie’s long-term pipeline and earnings outlook. Article Title Neutral Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for AbbVie to $14.08 from $14.23, though the new estimate remains close to the consensus of $14.18 and is not a major deviation. Article Title About AbbVie (Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

Featured Articles Five stocks we like better than AbbVie Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECantillon Capital Management LLC Reduces Stake in Liberty Media Corporation – Liberty Formula One Series C $FWONK

NEXT HEADLINE »419,463 Shares in State Street Blackstone High Income ETF $HYBL Purchased by Decker Wealth Management LLC

Posted by Defense World Staff on Jul 19th, 2026

AIA Group Ltd raised its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 23.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 74,580 shares of the company’s stock after buying an additional 14,163 shares during the period. AIA Group Ltd’s holdings in AbbVie were worth $16,220,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Norges Bank acquired a new position in AbbVie in the fourth quarter worth $5,865,055,000. Wellington Management Group LLP lifted its position in AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after buying an additional 8,646,424 shares in the last quarter. Capital World Investors grew its holdings in AbbVie by 106.3% during the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after acquiring an additional 6,736,161 shares during the last quarter. Cardano Risk Management B.V. increased its position in AbbVie by 914.6% in the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock valued at $1,244,112,000 after acquiring an additional 4,908,260 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in AbbVie by 10.4% in the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after acquiring an additional 4,190,487 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth A number of brokerages have recently issued reports on ABBV. DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Evercore set a $235.00 price objective on shares of AbbVie in a research report on Friday, May 15th. Canaccord Genuity Group upped their price objective on AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a report on Tuesday, June 23rd. HSBC reiterated a “buy” rating and issued a $300.00 price objective on shares of AbbVie in a research report on Monday, July 6th. Finally, Citigroup lifted their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $267.67.

Check Out Our Latest Report on AbbVie

AbbVie Trading Up 0.1% Shares of NYSE ABBV opened at $254.53 on Friday. The company has a fifty day moving average price of $229.80 and a 200 day moving average price of $221.94. The firm has a market cap of $449.70 billion, a PE ratio of 125.38, a PEG ratio of 0.84 and a beta of 0.30. AbbVie Inc. has a 1-year low of $184.63 and a 1-year high of $261.64.

AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter in the prior year, the company posted $2.46 earnings per share. The firm’s revenue was up 12.4% on a year-over-year basis. Equities research analysts forecast that AbbVie Inc. will post 14.18 EPS for the current year.

AbbVie Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s payout ratio is presently 340.89%.

Trending Headlines about AbbVie Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie’s Allergan Aesthetics unit won European Commission approval for Boey® (trenibotulinumtoxinE), a new facial injectable for glabellar lines. The approval gives AbbVie a differentiated aesthetics product in all 30 EEA countries and could add another growth driver to offset Humira-related declines. Article Title Positive Sentiment: Investors are also focusing on AbbVie’s neuroscience franchise and other newer product catalysts, with analysts expecting solid Q2 growth and continued momentum from brands such as Vyalev, RINVOQ, and SKYRIZI ahead of earnings. Article Title Positive Sentiment: Brokerage sentiment remains constructive, with recent coverage showing a “Moderate Buy” consensus and multiple price-target increases in July, reinforcing confidence in AbbVie’s long-term pipeline and earnings outlook. Article Title Neutral Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for AbbVie to $14.08 from $14.23, though the new estimate remains close to the consensus of $14.18 and is not a major deviation. Article Title About AbbVie (Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

Featured Articles Five stocks we like better than AbbVie Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAIA Group Ltd Sells 3,503 Shares of MercadoLibre, Inc. $MELI

NEXT HEADLINE »Geneos Wealth Management Inc. Makes New Investment in iShares MSCI USA Quality GARP ETF $GARP

Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹ Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks Boey® offers a differentiated treatment option for many people who are curious about facial injectables² , /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the European Commission has approved Boey® (trenibotulinumtoxinE) in Europe, for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines) in adult patients, when these have an important psychological impact.1

Following completion of the centralized procedure, the European Commission decision applies across all 30 European Economic Area (EEA) countries. Boey® also received approval in Canada in June of this year.

Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe. In clinical studies, onset of effect was observed as early as eight hours after treatment and effects lasted two to three weeks.

"The EU approval of Boey® marks an important step forward for our development program and builds on the momentum we've established with Health Canada's approval earlier this year," said Darin Messina, Ph.D., senior vice president, aesthetics research & development, AbbVie. "This milestone reflects the scientific rigor behind Boey® and reinforces our commitment to advancing innovative options as we work to bring this first-of-its-kind treatment to healthcare professionals and consumers around the world."

As interest in aesthetic treatments continues to grow, patients are increasingly seeking treatment options that align with their individual goals and preferences. An Allergan Aesthetics survey found that 80% of people are open to learning about new treatments to achieve their desired results, while 79% wish they could temporarily preview the outcome of an aesthetic treatment.3,* Despite this growing interest, many patients remain hesitant to take the next step due to uncertainty around treatment outcomes and concerns about committing to long-lasting results. Boey® was developed for patients considering treatment, offering another option to experience it before making a longer-term commitment.

Developed by the makers of BOTOX Cosmetic®, known as VISTABEL® or Vistabex® in the EU, Boey® offers a new option for suitable patients considering facial injectables. BOTOX Cosmetic® is the only neurotoxin clinically tested for safety following treatment with Boey®.1

Allergan Aesthetics is preparing to launch Boey® across Europe and will support healthcare professionals through education and training on the appropriate use of Boey®.

Allergan Aesthetics develops, manufactures and markets a portfolio of leading aesthetics brands and products. Allergan Aesthetics is well positioned to lead the future of injectable aesthetics, with dedicated research and development focused on driving innovation to meet the evolving needs of patients and healthcare professionals worldwide.

BOTOX® COSMETIC US APPROVED USES AND IMPORTANT SAFETY INFORMATION
BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, frown lines between the eyebrows, and vertical bands connecting the jaw and neck (platysma bands) in adults.

IMPORTANT SAFETY INFORMATION

BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

Problems swallowing, speaking, or breathing, due to weakening of associated muscles, which can be severe and result in loss of life. You are at the highest risk if these problems are preexisting before injection. Swallowing problems may last for several months.

Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms, including loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.

There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, forehead lines, and/or platysma bands.

BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of receiving BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

Serious and/or immediate allergic reactions have been reported, including itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or fain.

Do not receive BOTOX® Cosmetic if you are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc (rimabotulinumtoxinB), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA-xvfs), Daxxify (daxibotulinumtoxinA-lanm), or Letybo (letibotulinumtoxinA-wlbg); or have a skin infection at the planned injection site. This list may not include all available botulinum toxin products.

Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects, including difficulty swallowing and difficulty breathing, from standard doses of BOTOX® Cosmetic.

Tell your doctor about all your medical conditions, including surgery or plans to have surgery on your face, trouble raising your eyebrows, drooping eyelids, any other abnormal facial change, are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby), or are breastfeeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk).

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past.

Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; or take aspirin-like products or blood thinners.

Other side effects of BOTOX® Cosmetic include dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems, including double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of eyelids, and dry eyes.

For more information, refer to the Medication Guide or talk with your doctor.

To report a side effect, please call Allergan Aesthetics at 1-800-678-1605.

Please see BOTOX® Cosmetic full US Product Information, including Boxed Warning and Medication Guide.

About Boey®
Boey® is a facial injectable neurotoxin serotype E that targets SNAP-25. It has a rapid uptake and translocation into neuronal cells, with a short half-life of the type E light chain, giving it a rapid onset of action and a short duration of effect when treating glabellar lines.

About Boey® Clinical Trials
The approval of Boey® is supported by data from two randomised, multi-centre, double-blind, placebo-controlled studies Phase 3 clinical trials evaluating the efficacy and safety of Boey® in adults with moderate to severe glabellar lines (M21-500 and M21-508) associated with corrugator and/or procerus muscle activity, who were psychologically impacted by their glabellar lines. The studies enrolled 725 patients treated with Boey® 700 U total dose or placebo. The co-primary efficacy measure (treatment effect) was defined as the percentage of subjects achieving a ≥2-grade improvement from baseline in glabellar line severity at maximum frown based separately on investigator and subject assessments using the 4-point Facial Wrinkle Scale (FWS) (0=none, 1=mild, 2=moderate, 3=severe) at Day 7. Efficacy was assessed in the ITT population with baseline FLO-11 Total Transformed Score of ≤50. Secondary efficacy endpoints were measured by FLSQ, a scale developed by Allergan Aesthetics, and included satisfaction with achieving a natural look (Item 4) and overall satisfaction with treatment effect (Item 5).

The onset of effect for patients treated with Boey® appeared as early as 8 hours after injection in both pivotal studies. The peak effect was seen at Day 7 in both studies. Glabellar lines returned to baseline severity in approximately 2 to 3 weeks after administration. 

The adverse drug reactions associated with Boey® were eyelid ptosis, brow ptosis, and Mephisto sign (lateral elevation of eyebrow). These reactions were reported in 0.17%, 0.13%, and 0.04%, respectively, in subjects receiving Boey® 700 units.1

About Glabellar Lines
Glabellar lines are the vertical lines that appear between the eyebrows, commonly known as frown lines. In some adults, these lines can contribute to an appearance that is perceived as tired, angry or worried and may have an important psychological impact.

About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Footnotes 
*Customer survey research carried out across nine countries that included online data collection and a 20-minute self-administered closed questionnaire conducted between November to December 2025. 12,286 participants (Brazil 1,318, Canada 1,304, China 1,318, France 1,302, Germany 1,301, KSA 1,311, Thailand 1,321, USA 1,802 and UK 1,309) who have paid for at least two beauty or aesthetics-related services in the past year

References

Boey® Summary of Product Characteristics. AbbVie Ltd Allergan Aesthetics Holistic Beauty Global Research. REF-148616. January 2026. Allergan Aesthetics Holistic Beauty Global Research. REF-148616. January 2026. SOURCE AbbVie

AbbVie (ABBV - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the past month, shares of this drugmaker have returned +10%, compared to the Zacks S&P 500 composite's +1.6% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has gained 2.9%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, AbbVie is expected to post earnings of $3.68 per share, indicating a change of +23.9% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.8% over the last 30 days.

The consensus earnings estimate of $14.23 for the current fiscal year indicates a year-over-year change of +42.3%. This estimate has changed -0.6% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $16.12 indicates a change of +13.3% from what AbbVie is expected to report a year ago. Over the past month, the estimate has changed -1.1%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of AbbVie, the consensus sales estimate of $16.81 billion for the current quarter points to a year-over-year change of +9%. The $67.32 billion and $72.98 billion estimates for the current and next fiscal years indicate changes of +10.1% and +8.4%, respectively.

Last Reported Results and Surprise HistoryAbbVie reported revenues of $15 billion in the last reported quarter, representing a year-over-year change of +12.4%. EPS of $2.65 for the same period compares with $2.46 a year ago.

Compared to the Zacks Consensus Estimate of $14.78 billion, the reported revenues represent a surprise of +1.47%. The EPS surprise was +1.15%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

AbbVie is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about AbbVie (ABBV - Free Report) .

AbbVie currently has an average brokerage recommendation (ABR) of 1.61, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 32 brokerage firms. An ABR of 1.61 approximates between Strong Buy and Buy.

Of the 32 recommendations that derive the current ABR, 21 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 65.6% and 6.3% of all recommendations.

Brokerage Recommendation Trends for ABBV

Check price target & stock forecast for AbbVie here>>>

The ABR suggests buying AbbVie, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Is ABBV Worth Investing In?Looking at the earnings estimate revisions for AbbVie, the Zacks Consensus Estimate for the current year has declined 0.6% over the past month to $14.23.

Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for AbbVie. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, it could be wise to take the Buy-equivalent ABR for AbbVie with a grain of salt.

Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.

Key Takeaways: Big Pharma faces $300 billion in expiring drug patents through the decade. Total biopharma deal value could top $250 billion in 2026, the busiest year since 2019. SBIO’s June rebalance added 37 names ahead of a wave of trial and takeover news. According to PwC’s midyear deals outlook, more than $300 billion in branded pharmaceutical revenue will lose patent protection by the end of the decade. That loss, known as a loss of exclusivity, is pushing large drugmakers to buy new drug pipelines rather than build them in-house.

ALPS Advisors’ July spotlight shows the ALPS Medical Breakthroughs ETF (SBIO) holds mid-size biotech developers in that same targeted stage. That focus put the fund in the middle of June’s biggest headline. AbbVie Inc. (ABBV) agreed to pay $10.9 billion in cash for Apogee Therapeutics, Inc. (APGE), then SBIO’s largest holding.

See more: Biotech Gives SBIO Its Best Month Since 2023

PwC’s report also found large pharmaceutical companies are avoiding blockbuster mergers that draw heavy regulatory scrutiny. Midcap biotech bolt-on deals have become the sweet spot for dealmaking this year instead.

That shift is already showing up in the numbers. Total biopharma deal value is on pace to top $250 billion in 2026, according to PitchBook data cited by ALPS Advisors. That would mark the industry’s strongest year since 2019.

Regulatory news added another tailwind. On June 17, the FDA signaled a more flexible approval path for serious and rare diseases, according to ALPS Advisors. Days later, Definium Therapeutics Inc. (DFTX) raised an upsized $700 million in stock to fund its own drug submission. It chose capital over a buyout.

Inside SBIO’s Biotech Screening Rulesss SBIO tracks an index limited to U.S. biotech companies worth between $200 million and $5 billion, according to ALPS Advisors. Each company must have a drug in Phase II or Phase III FDA trials. Each must also hold enough cash to fund about two years of operations.

Broader benchmarks such as the NASDAQ Biotechnology Index lean toward the large-cap companies writing acquisition checks, according to ALPS Advisors. SBIO’s index sits on the other side of those deals, holding the smaller companies, which are usually the ones getting bought.

Twice a year, the fund’s index rebalances to keep pace. Its June 18 update added 37 companies and dropped 15, according to ALPS Advisors. That turnover brought Definium into the fund just four days before its trial results sent shares up more than 90%.

For more news, information, and strategy, visit the ETF Building Blocks Content Hub.

VettaFi LLC (“VettaFi”) is the index provider for SBIO, for which it receives an index licensing fee. However, SBIO is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of SBIO.

AbbVie (ABBV 0.73%) is listed as a Dividend King, but in fairness, it has only been a stand-alone company since it was spun off from Abbott (ABT 0.46%) at the start of 2013. AbbVie hasn't been around for the 50 years required to qualify as a Dividend King; instead, it has inherited Abbott's track record. Still, it has increased its dividend annually since the spin-off.

So the real story is what AbbVie has been doing to maintain its place among the Dividend Kings. The most recent answer to that is to agree to buy Apogee Therapeutics (APGE +0.06%). Here's why that's so important for the future.

Image source: Getty Images.

AbbVie has a strong portfolio, for now AbbVie has a strong portfolio of drugs. Biologics are a big part of its business, with Humira, Skyrizi, and Rinvoq all notable products. The interesting thing about this trio is that Humira lost patent protection in 2023, leading to a decline in its revenues. But Skyrizi and Rinvoq are newer drugs and helping to pick up the slack. This is how the pharmaceutical sector works: companies like AbbVie are always on the lookout for new drugs to replace older ones that will eventually lose patent protection.

The purchase of Apogee Theraputics brings with it a number of attractive drug candidates. AbbVie highlighted zumilokibart, a late-stage drug for atopic dermatitis, in its release. This is a core therapeutic area for AbbVie. But the release also noted Apogree's pipeline of drugs in the respiratory space, which could help to build AbbVie's presence in this area.

Today's Change

(

-0.73

%) $

-1.83

Current Price

$

248.08

Simply put, this $10.9 billion deal highlights AbbVie's ability to support its drug pipeline, which is what will allow it to maintain its Dividend King status over time. What's interesting here, and sets AbbVie apart from most of its competitors, is that the company also makes Botox, which was an acquired product as well. Botox is off-patent, but it has an important brand name in the cosmetic space. That gives the company a consistent revenue stream, which is unusual in the drug space. And it makes Botox a good example of AbbVie's ability to make strong acquisitions.

Is AbbVie a dynasty in the making? Some of the world's best-known drug companies have been in business for over 100 years. AbbVie obviously isn't at that point yet. However, the Apogee Therapeutics acquisition shows, again, why it can compete with much older drug-makers. With an attractive 2.7% dividend yield, AbbVie is a worthwhile deep dive for conservative dividend lovers who think in decades.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© scyther5 / iStock via Getty Images

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that reshape how income investors should think about big pharma.

JNJ paired a top-line beat with a raised full-year outlook and a 64th consecutive dividend increase. AbbVie beat on revenue, missed on EPS due to a pipeline charge, and leaned harder into immunology. Same quarter, very different playbooks.

Oncology Powers One. Immunology Powers the Other. JNJ pulled in $24.06 billion in revenue, up 9.9% YoY, with adjusted EPS of $2.70 beating the $2.6773 consensus. Oncology carried the quarter: DARZALEX hit $3.96 billion (+22.5%), CARVYKTI grew 62.1%, and TREMFYA absorbed STELARA share with 68.3% growth.

STELARA itself fell 59.7%, a roughly 920 basis point drag on Innovative Medicine. MedTech added $8.64 billion with cardiovascular up 13.0%. CEO Joaquin Duato called the portfolio and pipeline “unrivaled” after approvals for ICOTYDE and VARIPULSE Pro.

AbbVie posted $15 billion in revenue, up 12.43% YoY, with Skyrizi at $4.48 billion (+30.9%) and Rinvoq at $2.12 billion (+23.3%). Humira slid 38.6%, and adjusted EPS of $2.65 came in a hair below the $2.6676 estimate after a $744 million IPR&D charge shaved $0.41 per share. Neuroscience surprised, growing 26% on Botox Therapeutic, Ubrelvy and Qulipta.

Diversified Compounder vs. Immunology Machine Lens JNJ ABBV Core Bet Oncology + MedTech Skyrizi and Rinvoq scaling past Humira 2026 EPS Guide $11.45 to $11.65 $14.08 to $14.28 Forward P/E 23 18 Dividend Yield 2.01% 2.65% Key Vulnerability STELARA biosimilar erosion Humira erosion, IPR&D lumpiness JNJ is running a diversified compounder strategy, funding a planned Orthopaedics separation and a $1+ billion Pennsylvania cell therapy plant while raising its dividend 3.1% to $1.34. AbbVie is pouring $1.4 billion into a Durham, NC campus and pushing the non-incretin ABBV-295 obesity program toward the GLP-1 conversation.

July 16 is the Final Day to Tap Into the Lithium Boom (sponsor)
General Motors, POSCO, and 50,000+ everyday investors have already backed lithium producer EnergyX. 

Here’s why you should do the same before their July 16 investment deadline: lithium prices are up 75% this year, with demand projected to grow a staggering 5X by 2040. 

With tech that can recover up to 3X more lithium than traditional methods, EnergyX is preparing to unlock up to 15M+ tons. Become a private-stage EnergyX investor before the July 16 deadline.

CEO Robert A. Michael said the results were “exceeding our expectations”. Fair enough, but the IPR&D charge is a reminder that AbbVie’s earnings quality can swing more than JNJ’s.

Next Test Arrives July 15 for JNJ JNJ reports Q2 on July 15, 2026, with Polymarket traders pricing a 92% probability of beating the $2.85 consensus. MedTech is the swing factor: traders cluster around a $9 billion revenue threshold at 71% odds.

For AbbVie, I want cleaner Skyrizi and Rinvoq numbers without another IPR&D surprise, plus early Phase 1 clarity on ABBV-295 before assuming obesity optionality is real.

Why I Split the Two by Investor Type If I wanted a defensive core position with visible cash return, JNJ fits the profile. The $5.36 annualized dividend, low 0.235 beta, and MedTech optionality earn a steady seat in the portfolio, even after a 73.3% one-year run that has stretched the setup.

If I wanted more growth torque and a fatter yield, AbbVie is the more growth-oriented profile. Skyrizi and Rinvoq are outrunning Humira’s decay, and the 2.65% yield plus 18 forward P/E fits a growth-plus-income buyer. Investors may want to monitor both if IPR&D noise or STELARA erosion accelerates before the next earnings report.

Meet America's Newest $1b Unicorn (Sponsor)A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.

Over 50,000 people already have, along with global giants like General Motors and POSCO.

Here’s why there’s so much interest: EnergyX’s patented tech can recover up to 3X more lithium than traditional methods. That’s a big deal, as demand for lithium is expected to 5X current production levels by 2040.Become an early-stage EnergyX shareholder before the 7/16 investment deadline.

Contact [email protected] for any questions or corrections.

Key Takeaways AbbVie won EU approval for Tepkinly R2 in adult patients with R/R FL after prior therapy.ABBV's phase III study showed a 79% lower risk of progression or death versus R2 alone, with higher responses.AbbVie and Genmab continue to advance epcoritamab across blood cancers through late-stage clinical studies. AbbVie (ABBV - Free Report) announced that the European Commission (EC) approved the expanded use of Tepkinly (epcoritamab) for the relapsed or refractory follicular lymphoma (R/R FL) indication. The EC approved the drug in combination with rituximab and lenalidomide (Tepkinly+R2) for adult patients with R/R FL after at least one line of systemic therapy.

The approval represents Tepkinly's third indication in the European Union (EU) and marks the first EU approval of a bispecific-based, chemotherapy-free therapy for second-line relapsed or refractory follicular lymphoma.

To remind investors, ABBV markets epcoritamab under the brand name Epkinly in the United States and Japan, and as Tepkinly in the EU.

Tepkinly is already approved as monotherapy for adults with relapsed or refractory diffuse large B-cell lymphoma and R/R FL after two or more lines of systemic therapy in the EU.

The FDA approved Epkinly in combination with rituximab and lenalidomide for a similar indication in the United States in November 2025.

Year to date, ABBV shares have rallied 11.5% compared with the industry’s 13.8% growth.

Image Source: Zacks Investment Research

ABBV's Tepkinly Combo EU Nod Backed by Phase III StudyThe EU approval is based on data from the pivotal phase III EPCORE FL-1 study, which demonstrated that Tepkinly+R2 significantly improved outcomes compared to the standard-of-care R2 alone in second-line patients with R/R FL. The combination reduced the risks of disease progression or death by 79% and achieved higher overall and complete response rates versus R2 alone. Its safety profile was consistent with the known profiles of the previous individual therapies, with no new safety signals identified.

The most common adverse events included neutropenia, rash, infections, fatigue, diarrhea, COVID-19 and cytokine release syndrome, while serious adverse events occurred in 44% of patients.

Follicular lymphoma is a slow-growing type of B-cell non-Hodgkin lymphoma and the second most common subtype of the disease. Although treatment can induce remission, FL remains incurable, with many patients experiencing relapses and requiring additional therapies over time. The disease is more prevalent in European populations than in non-European populations.

AbbVie has partnered with Genmab (GMAB - Free Report) to jointly develop epcoritamab under the companies' oncology collaboration agreement. While both companies share commercialization rights in the United States and Japan, AbbVie is responsible for commercialization in other global markets. AbbVie and Genmab continue to advance their global development and regulatory expansion while evaluating the therapy as a monotherapy and in combination regimens across multiple hematologic malignancies through several late-stage clinical studies.

ABBV’s Zacks Rank & Stocks to ConsiderAbbVie currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Immunocore (IMCR - Free Report) and Amarin Corporation (AMRN - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents per share. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 8% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.

Over the past 60 days, loss per share estimates for Amarin have narrowed from $15.20 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $13.00 to 51 cents for 2027. AMRN shares have risen 12.5% year to date.

Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.

The iShares Core High Dividend ETF (HDV 1.21%) isn't as large or as popular as other dividend ETFs. As a result, many investors have likely missed that the fund is outperforming the S&P 500 this year. While that broad market index was up a strong 9% through the first half of the year, HDV is up more than 15%.

Here's a closer look at this top ETF and what has driven its quiet outperformance so far this year.

Image source: Getty Images.

High-quality, high-yielding dividend stocks The iShares Core High Dividend ETF is a passively managed fund that tracks an index of high-yielding U.S. dividend stocks (Morningstar Dividend Yield Focus Index). That index doesn't just screen companies based on their dividend yield. It also applies additional financial quality screens, including having a wide economic moat (sustainable competitive advantage) and a high distance to default (strong financial health). The index selects the highest-yielding stocks from those that pass its quality screens. It weights stocks in proportion to the dividends they pay.

The net result is an ETF that currently holds 75 stocks. The iShares Core High Dividend ETF has a 2.9% dividend yield based on its current price and dividend payments over the last 12 months. That's nearly three times higher than the S&P 500's current dividend yield of 1.1%.

Today's Change

(

-1.21

%) $

-0.34

Current Price

$

27.70

The ETF's top five holdings are:

ExxonMobil: 7.1% weighing in the ETF. AbbVie (ABBV 2.44%): 6.6% Chevron: 5.4% Verizon: 5.1% Home Depot: 4.9% While two of its top three holdings are energy stocks, the fund's overall allocation to the energy sector is 12.2% (third-largest sector). Consumer staples 24.5% and healthcare (23.9%) are its largest sectors.

Today's Change

(

-2.44

%) $

-6.37

Current Price

$

254.70

What's driving the strong performance in 2026? The fund's relatively high exposure to the energy sector has helped drive its outperformance this year. The Iran war initially drove up oil prices, fueling a rally in oil stocks. For example, shares of ExxonMobil and Chevron are up 14% and 11%, respectively, this year, outperforming the S&P 500.

However, oil isn't the only factor driving HDV's quiet outperformance this year. The fund has also benefited from its high exposure to healthcare stocks, notably AbbVie and Merck (MRK 2.15%), the latter of which is its 9th-largest holding at 4.1%. Shares of AbbVie have gained more than 14% while Merck has rallied over 23%. AbbVie reported a 12.4% increase in first-quarter revenue, driven by the strength of its immunology (up 16.4%) and neuroscience portfolios (up 26%). AbbVie also took a step to deepen its immunology portfolio by recently agreeing to acquire Apogee Therapeutics for $10.9 billion. Meanwhile, Merck reported 5% sales growth in the first quarter, driven by a 12% increase in Keytruda sales. The company also strengthened its oncology pipeline by acquiring Terns Pharmaceutical for $6.7 billion.

High-yielding dividend stocks can also yield higher returns Many investors view high-yielding dividend stocks as lower-returning investments. However, that's not always the case. High-quality, high-yielding dividend stocks can often deliver high total returns as they grow their earnings and payouts. HDV's focus on high-quality dividend stocks such as Exxon, Chevron, AbbVie, and Merck has paid off this year as they've helped the fund quietly outperform the S&P 500. With more income and growth ahead, the iShares Core High Dividend ETF should continue to quietly deliver strong returns (it has delivered more than 10% annualized returns over the last one-, three-, and five-year periods as well as since its inception in 2011).

Matt DiLallo has positions in Chevron, Home Depot, and Verizon Communications. The Motley Fool has positions in and recommends AbbVie, Chevron, Home Depot, and Merck. The Motley Fool recommends Verizon Communications. The Motley Fool has a disclosure policy.

Key Takeaways AbbVie's Q2 results will hinge on Skyrizi and Rinvoq as Humira sales continue to decline.ABBV expects Skyrizi and Rinvoq momentum, backed by market share gains, to lift immunology sales.AbbVie is expanding in oncology and neuroscience while facing immunology competition from J&J and Lilly. AbbVie (ABBV - Free Report) remains a dominant force in the immunology segment, from where it generates nearly half of its top line. This growth is mainly driven by the continued uptake of its two blockbuster medications, Skyrizi and Rinvoq, which have helped the company return to top-line growth despite the U.S. loss of exclusivity for its legacy drug, Humira, in 2023. Investors’ focus will primarily be on the sales performance of these two drugs when AbbVie reports its second-quarter 2026 results on July 31.

The Zacks Consensus Estimate for Skyrizi sales is pegged at $5.49 billion, while the same for Rinvoq stands at $2.47 billion. Continued momentum from these therapies, supported by market share gains, is expected to drive immunology sales in the quarter. Meanwhile, Humira sales are expected to continue their downward trajectory, with the Zacks Consensus Estimate pegged at $744 million for the quarter.

AbbVie successfully launched Skyrizi and Rinvoq across Humira's major indications, as well as a distinct new indication, atopic dermatitis. Both drugs have delivered strong performance across approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes ulcerative colitis (UC) and Crohn’s disease (CD).

The company has also been expanding its presence beyond immunology into oncology and neuroscience. In recent years, ABBV has added Elahere, Emrelis and, most recently, Decnupaz, bringing its total number of oncology therapies to six. Growth in its neuroscience segment has also been supported by the increasing uptake of its migraine drugs, Ubrelvy and Qulipta, as well as the Parkinson’s disease drug Vyalev.

ABBV’s Competition in the Immunology SpaceThe immunology market is highly competitive. A key player in this area is Johnson & Johnson (JNJ - Free Report) , which already markets two blockbuster drugs — Stelara and Tremfya. These medications are approved across multiple immunology indications, including UC and CD. Since Stelara lost U.S. patent exclusivity last year, J&J has shifted its focus to Tremfya. It recently secured approval for a new immunology drug, Icotyde, to treat moderate-to-severe plaque psoriasis. While still in the early stages of launch, the drug could pose a competitive threat to Skyrizi.

Another pharma giant expanding its presence in immunology is Eli Lilly (LLY - Free Report) , following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked LLY’s first immunology drug approved for a type of IBD in the United States, playing a key role in expanding its immunology portfolio. The Eli Lilly drug is approved for the CD indication.

ABBV’s Price Performance, Valuation and EstimatesShares of AbbVie have outperformed the industry year to date, as seen in the chart below.

Image Source: Zacks Investment Research

From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 17.2 times forward earnings, lower than its industry’s average of 19.1.

Image Source: Zacks Investment Research

The bottom-line estimate per share for 2026 has declined from $14.30 to $14.28, while the 2027 estimate has fallen from $16.30 to $16.03 over the past 30 days.

Image Source: Zacks Investment Research

AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Dividend investors entering July 2026 have a rare setup: Three of the market’s most reliable income stocks all delivered beat-and-raise first-quarter reports, all hiked their payouts in the past 12 months and all three are riding meaningful momentum into the back half of the year. The thesis is simple. When defensive cash-flow machines start outperforming, income compounding does the heavy lifting while you wait.

Here are three dividend names worth watching closely this month, each chosen for a different reason so they complement rather than duplicate each other in a portfolio.

AbbVie (ABBV) AbbVie (NYSE:ABBV | ABBV Price Prediction) is the growth-flavored pick of the three. The post-Humira transition is no longer theoretical: Skyrizi posted $4.48 billion in Q1 sales (+31%) and Rinvoq added $2.12 billion (+23%), more than offsetting a 39% Humira decline. Total Q1 2026 revenue hit $15.00 billion, up 12% year-over-year, and management lifted full-year adjusted EPS guidance to $14.08 to $14.28.

The dividend math is what matters here: AbbVie now pays $1.73 per share quarterly, up from $1.64 in 2025 and the streak runs 12 consecutive years as a standalone company since the Abbott spin. Shares are trading around $252 with a forward P/E of 18, which is reasonable given the trailing growth profile. CEO Robert A. Michael said the company is “off to an excellent start in 2026, with first-quarter results exceeding our expectations.”

Bull case: Skyrizi and Rinvoq are now collectively bigger than Humira ever was at peak, neuroscience grew 26%, and the 44% one-year total return shows the market is finally crediting the new growth engines.

Risk: Humira erosion is not finished, a $744 million IPR&D charge dragged Q1 net income lower by 46% year-over-year, and the trailing P/E of 124 reflects how lumpy GAAP earnings can be in biopharma.

Johnson & Johnson (JNJ) Johnson & Johnson (NYSE:JNJ) is the quality anchor. The company just raised its quarterly dividend to $1.34 from $1.30, extending a streak that now sits at 64 consecutive years of annual increases. That makes JNJ a true Dividend King, and it carries one of only two AAA corporate credit ratings in the United States.

Q1 2026 was a clean beat. Revenue came in at $24.06 billion (+10% YoY), adjusted EPS of $2.70 beat the $2.68 consensus, and management raised full-year guidance to revenue of $100.3 billion to $101.3 billion with adjusted EPS of $11.45 to $11.65. Oncology is the engine: DARZALEX grew 23%, TREMFYA jumped 68% and CARVYKTI climbed 62%. CEO Joaquin Duato called it “a year of accelerated growth and impact.”

Bull case: A beta of 0.256 gives the portfolio ballast, oncology growth is offsetting STELARA biosimilar pressure, and the stock has already delivered a 26% YTD return while still trading below the $257.50 analyst target.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn't make the cut. Grab the names FREE today.

Risk: STELARA created roughly 920 basis points of revenue drag, talc-related litigation produced a $330 million Q1 charge, and the planned Orthopaedics separation introduces execution risk.

Coca-Cola (KO) Coca-Cola (NYSE:KO) rounds out the trio as the pure defensive staple. The current quarterly payout sits at 53 cents, with the next payment dated July 1. Coca-Cola has now raised its dividend for 64 consecutive years, paid $8.8 billion in dividends during 2025 and remains Berkshire Hathaway’s third-largest holding.

Q1 2026 was the cleanest report of the three. Revenue of $12.47 billion (+12% YoY) beat estimates, EPS of 86 cents beat the 81-cent consensus, organic revenue grew 10% and operating margin expanded to 35% from 33%. Coca-Cola Zero Sugar volume grew 13%. Management raised 2026 comparable EPS growth guidance to 8% to 9% and expects free cash flow near $12.2 billion. New CEO Henrique Braun summarized it: “We’ve had a strong start to the year.”

Retail interest tracks the fundamentals. Reddit sentiment on r/dividendinvesting registered scores of 70 to 72 in early June, with a 62 bullish reading on June 25.

Bull case: A beta of 0.354, raised EPS guidance, and global unit case volume growth led by China, the U.S. and India give KO an unusual combination of stability and modest top-line acceleration. Shares are up 20% YTD at $81.98.

Risk: A $960 million BODYARMOR impairment hit Q4 2025, ongoing IRS tax litigation remains unresolved, and the forward P/E of 25 leaves limited multiple expansion upside if growth slows.

What to Watch in July The next catalysts arrive quickly. Coca-Cola pays its quarterly dividend July 1, AbbVie’s next ex-dividend date is July 15, and second-quarter earnings season kicks off mid-month. With all three names having raised guidance in Q1, the bar for July reports is whether momentum holds.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

AbbVie is acquiring Apogee Therapeutics for $10.9B, reinforcing its immunology franchise and addressing future patent cliffs proactively. Skyrizi and Rinvoq have already replaced Humira's revenue, with combined sales surpassing Humira's peak and continuing to grow at 20–30% post-LOE. Zumilokibart, Apogee's lead asset, offers best-in-class efficacy and dosing convenience in atopic dermatitis, with Phase 3 data expected in 2028 and approval in 2030.

Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial.

The trial evaluated the combination of fixed-duration epcoritamab and lenalidomide, compared to standard-of-care, rituximab plus gemcitabine plus oxaliplatin (R-GemOx), in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received at least one prior line of treatment.

• Genmab stock is surging to new heights today. Why is GMAB stock up today?

Genmab and AbbVie Inc. (NYSE:ABBV) continue to evaluate epcoritamab as a monotherapy and in combination across lines of therapy in a range of hematologic malignancies.

Phase 3 Trial Meets Primary Progression-Free Survival GoalThe trial met its primary objective, demonstrating statistically significant and clinically meaningful improvement in progression-free survival (PFS).

The risk of disease progression and death was reduced by 60% (HR 0.40) and 56% (HR 0.44), based on different censoring rules in the U.S. and outside the U.S., respectively.

The safety profile of epcoritamab when administered in combination with lenalidomide was consistent with the previously reported safety profiles of the individual agents (epcoritamab or lenalidomide).

Convenience AdvantageWilliam Blair on Monday wrote, “Importantly, the HR is largely consistent across both approaches, and shows meaningful improvements over standard-of-care R-GemOx. In addition, the efficacy is roughly on par with comparator regimens but with key advantages on convenience that we believe may support stronger physician adoption.”

Analyst Sees Label Expansion and Larger Market OpportunityAnalyst Matt Phipps said the positive EPCORE DLBCL-4 results support a potential label expansion into the second-line-plus DLBCL population, which Genmab estimates at about 21,000 patients.

He added that the data also boosts confidence in the Phase 3 EPCORE DLBCL-2 trial in frontline DLBCL, expected to read out in 2026 and targeting a significantly larger market of roughly 70,000 patients.

William Blair sees the potential for up to $8 billion in revenue for these three assets alone, including Darzalex, Kesimpta, and Tecvayli.

Phipps expects the three drugs to drive significant upside to the company’s current market cap of just over $16 billion, and therefore rates Genmab Outperform.

GMAB Stock Price Activity: Genmab shares were up 5.65% at $27.49 at the time of publication on Tuesday, according to Benzinga Pro data.

Photo: Gorodenkoff via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a Reuters report.

The inquiry, led by Republican Representative John Moolenaar of Michigan, chair of the House Select Committee on China, focuses on whether the drugmakers conducted adequate due diligence and maintained sufficient data protection standards at trial sites in China.

In letters dated Monday and first reported by Reuters on Tuesday, lawmakers requested detailed information from Merck & Co Inc (NYSE:MRK, XETRA:6MK) and Abbvie Inc (NYSE:ABBV) by July 17, including documentation on research practices, safeguards, and oversight mechanisms.

The scrutiny also extends to Eli Lilly and Co (NYSE:LLY), Pfizer Inc (NYSE:PFE, XETRA:PFE), and Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP), which received similar requests from the committee.

Lawmakers specifically asked for information related to clinical trial locations in China, including sites in the Xinjiang region and military-affiliated hospitals, and raised broader concerns about whether sensitive biomedical data could be accessed or repurposed in ways that pose national security risks.

Merck stated that patient safety and ethical integrity are central to its clinical research operations and said it adheres to global regulatory standards governing clinical trials. AbbVie declined to comment. Pfizer confirmed receipt of the letter but did not provide further comment. Bristol Myers Squibb and Eli Lilly did not immediately respond to requests for comment, according to the Reuters report.

The Chinese embassy in Washington rejected the premise of the investigation, saying in an email that there is “nothing credible” in the committee’s actions and reiterating opposition to what it described as efforts to politicize trade and technology issues.

The developments add to growing US-China tensions over scientific collaboration, particularly in sectors involving sensitive data and dual-use technologies, where commercial research may intersect with national security concerns.

The companies’ shares initially moved lower following the news, but were little changed by the early afternoon.

Topline results from Phase 3 EPCORE ® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) EPCORE DLBCL-4 demonstrated improved PFS with a chemotherapy-free combination treatment regimen in patients with R/R DLBCL NORTH CHICAGO, Ill., June 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell engaging bispecific antibody, and lenalidomide, compared to rituximab plus gemcitabine plus oxaliplatin (R-GemOx) in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received at least one prior line of therapy.

When a stock hits a new 52-week high, it can be a sign that things are going well for the business and that investors are recognizing some encouraging value. However, it also means that the stock has become more expensive of late. Thus, it isn't always clear whether it's a good buy, since buying a stock at an elevated price can lead to less-than-stellar returns later on.

Healthcare giant AbbVie (ABBV +0.26%) hit a new 52-week high on Monday. And in the past 12 months, it's now up around 40%. Can it go even higher, or has its valuation become too rich to make it a good buy?

Image source: Getty Images.

Why a rally for AbbVie may have been overdue While it may seem like AbbVie has become a hot stock of late, given that it has hit new highs, on a year-to-date basis, it has risen by just around 11%. That's better than the S&P 500's gains of about 8%, but it hasn't been taking off the way some top growth stocks have.

Given the company's level of earnings, the stock should arguably have been trading at a higher price than it has. Even with its rise in value this year, the stock trades at less than 18 times its estimated future earnings (based on analyst expectations). This is still below the S&P 500 average of 21.

Due to concerns about healthcare reform under the current administration, investors may have been a bit hesitant to load up on the stock. But with AbbVie continually reporting strong numbers, it's been demonstrating solid resiliency, reminding investors as to why it's a top blue chip stock to own.

Today's Change

(

0.26

%) $

0.65

Current Price

$

254.00

It isn't too late to buy AbbVie stock AbbVie is a growth beast as it continues to expand its business through acquisitions. Most recently, it announced a $10.9 billion acquisition of Apogee Therapeutics, which will expand its immunology portfolio. While acquisition-related expenses can weigh on its earnings, in the long run, they enable the pharmaceutical giant to diversify and generate some impressive results. along the way.

With an attractive valuation, strong financials, an appetite for more growth, and an above-average dividend that yields 2.7%, AbbVie makes for a terrific all-around stock to buy and hold for the long run. Although its share price may seem inflated, being that it's at a new 52-week high, it's not too late to buy the stock, especially if you're planning to hang on to it for the long haul.

Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score ≤ 20 and key secondary endpoints, including improvements in eyebrows and eyelashes, at week 241,2 Upadacitinib is the first JAK inhibitor to meet the stringent ranked secondary endpoint of complete scalp hair regrowth (SALT = 0) at week 241,2 , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA). The final European Commission decision is expected in the coming months.

"Alopecia areata is an unpredictable autoimmune disease with underrecognized patient burden," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "The CHMP's positive opinion for upadacitinib is a step closer to bringing a new treatment option to patients living with severe alopecia areata." 

The CHMP positive opinion is supported by data from the ongoing Phase 3 UP-AA clinical program (M23-716), which includes two replicate, randomized, placebo-controlled, double-blind studies evaluating the efficacy and safety of upadacitinib in adult and adolescent patients with severe alopecia areata. Both the 15 mg and 30 mg doses of upadacitinib in each study met the primary endpoint of SALT score ≤ 20 at week 24, with significantly more patients achieving ≥ 80% scalp hair coverage compared with placebo. Key secondary endpoints were also met for both doses in both studies, including complete scalp hair regrowth (SALT = 0) at week 24. The safety profile of both doses of upadacitinib in Period A was generally consistent with that observed in approved indications.1,2

Upadacitinib is approved in the European Union (EU) for the treatment of adults and adolescents with atopic dermatitis, and adults with radiographic axial spondylarthritis, non-radiographic axial spondylarthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, and giant cell arteritis. Use of upadacitinib in AA is not currently approved in the EU.  

About Alopecia Areata
Alopecia areata (AA) is an unpredictable autoimmune disease causing a range of hair loss patterns, from sudden, round bald patches on the scalp to complete loss of all body hair, including scalp, face, eyebrows and eyelashes.3,4 Despite its immune-mediated nature, AA is often considered a cosmetic problem, which can lead to stigma and have an impact on patients' lives.5,6 

About UP-AA Clinical Trial 
UP-AA M23-716 was conducted as a single protocol that includes two replicate pivotal studies (Study 1 and Study 2) with randomization, investigative sites, data collection, analysis and reporting independent for each study. The Phase 3 randomized, placebo-controlled, double-blind studies evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata. In Study 1 and Study 2 Period A, participants are randomized to one of three groups to receive upadacitinib 15 mg, upadacitinib 30 mg or placebo for 24 weeks. In Study 1 and Study 2 Period B, participants originally randomized to upadacitinib dose groups in Period A will continue their same treatment in Period B for 28 weeks. Participants originally randomized to placebo in Period A will either remain on placebo in Period B, or be randomized in one of two groups, based on their SALT score at week 24. In total, Study 1 and Study 2 Periods A and B span 52 weeks. Participants who complete Study 1 or Study 2 can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. The two trials randomized 1,399 participants with severe AA ages 12 to 64 across 248 sites worldwide. More information on this trial can be found at www.clinicaltrials.gov (NCT06012240).

About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs JAK-2, JAK-3, and TYK-2. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known.

Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for alopecia areata, hidradenitis suppurativa, Takayasu arteritis, systemic lupus erythematosus, and vitiligo. The use of upadacitinib in alopecia areata is not approved; its safety and efficacy are under regulatory review by the U.S. FDA and the European Medicines Agency.

EU Indications and Important Safety Information about RINVOQ® (upadacitinib)7

Indications

Rheumatoid arthritis

RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Psoriatic arthritis

RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Axial spondyloarthritis

Non-radiographic axial spondyloarthritis (nr-axSpA)

RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)

RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Giant cell arteritis

RINVOQ is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

Atopic dermatitis

RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.

Ulcerative colitis

RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Crohn's disease

RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Important Safety Information

Contraindications
RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.

Special warnings and precautions for use
RINVOQ should only be used if no suitable treatment alternatives are available in patients:

65 years of age and older; patients with history of atherosclerotic cardiovascular (CV) disease or other CV risk factors (such as current or past long-time smokers); patients with malignancy risk factors (e.g. current malignancy or history of malignancy) Use in patients 65 years of age and older
Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients ≥65 years of age, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available. In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily.

Immunosuppressive medicinal products
Use in combination with other potent immunosuppressants is not recommended.

Serious infections
Serious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis and sepsis have been reported with RINVOQ. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis have been reported. RINVOQ should not be initiated in patients with an active, serious infection, including localized infections. RINVOQ should be interrupted if a patient develops a serious or opportunistic infection until the infection is controlled. A higher rate of serious infections was observed with RINVOQ 30 mg compared to 15 mg. As there is a higher incidence of infections in the elderly and patients with diabetes in general, caution should be used when treating these populations. In patients ≥65 years of age, RINVOQ should only be used if no suitable treatment alternatives are available.

Tuberculosis
Patients should be screened for TB before starting RINVOQ. RINVOQ should not be given to patients with active TB. Anti-TB therapy may be appropriate for select patients in consultation with a physician with expertise in the treatment of TB. Patients should be monitored for the development of signs and symptoms of TB.

Viral reactivation
Viral reactivation, including cases of herpes zoster, was reported in clinical studies. The risk of herpes zoster appears to be higher in Japanese patients treated with RINVOQ. Consider interruption of RINVOQ if the patient develops herpes zoster until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.

Vaccination
The use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.

Malignancy
Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate of malignancies, including NMSC, was observed with RINVOQ 30 mg compared to 15 mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In patients ≥65 years of age, patients who are current or past long-time smokers, or patients with other malignancy risk factors (e.g., current malignancy or history of malignancy), RINVOQ should only be used if no suitable treatment alternatives are available.

Hematological abnormalities
Treatment should not be initiated, or should be temporarily interrupted, in patients with hematological abnormalities observed during routine patient management.

Gastrointestinal perforations
Events of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from post-marketing sources. RINVOQ should be used with caution in patients who may be at risk for gastrointestinal perforation (e.g., patients with diverticular disease, a history of diverticulitis, or who are taking non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or opioids. Patients with active Crohn's disease are at increased risk for developing intestinal perforation. Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.

Major adverse cardiovascular events
MACE were observed in clinical studies of RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of MACE, defined as CV death, non-fatal myocardial infarction and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors. Therefore, in patients ≥65 years of age, patients who are current or past long-time smokers, and patients with history of atherosclerotic CV disease or other CV risk factors, RINVOQ should only be used if no suitable treatment alternatives are available.

Lipids
RINVOQ treatment was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.

Hepatic transaminase elevations
Treatment with RINVOQ was associated with an increased incidence of liver enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.

Venous thromboembolism
Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a dose‑dependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors. In patients with CV or malignancy risk factors, RINVOQ should only be used if no suitable treatment alternatives are available. In patients with known VTE risk factors other than CV or malignancy risk factors (e.g. previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder), RINVOQ should be used with caution. Patients should be re-evaluated periodically to assess for changes in VTE risk. Promptly evaluate patients with signs and symptoms of VTE and discontinue RINVOQ in patients with suspected VTE.

Retinal vein occlusion
Retinal vein occlusion has been reported in patients treated with JAK inhibitors, including upadacitinib. Patients should be advised to promptly seek medical care in case they experience symptoms suggestive of retinal vein occlusion.

Hypersensitivity reactions
Serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving RINVOQ. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.

Hypoglycemia in patients treated for diabetes
There have been reports of hypoglycemia following initiation of JAK inhibitors, including RINVOQ, in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycemia occurs.

Medication Residue in Stool
Reports of medication residue in stool or ostomy output have occurred in patients taking RINVOQ. Most reports described anatomic (e.g., ileostomy, colostomy, intestinal resection) or functional gastrointestinal conditions with shortened gastrointestinal transit times. Patients should be instructed to contact their healthcare professional if medication residue is observed repeatedly. Patients should be clinically monitored, and alternative treatment should be considered if there is an inadequate therapeutic response.

Giant Cell Arteritis
RINVOQ monotherapy should not be used for the treatment of acute relapses as efficacy in this setting has not been established. Corticosteroids should be given according to medical judgement and practice guidelines.

Adverse reactions
The most commonly reported adverse reactions in RA, PsA, and axSpA clinical trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients with psoriatic arthritis or active axial spondyloarthritis treated with RINVOQ 15 mg was consistent with the safety profile observed in patients with RA.

The most commonly reported adverse reactions in AD trials (≥2% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza. Dose dependent increased risks of infection and herpes zoster were observed with RINVOQ. The safety profile for RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.

The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne, herpes zoster, neutropenia, rash, pneumonia, hypercholesterolemia, bronchitis, AST increased, fatigue, folliculitis, ALT increased, herpes simplex, and influenza. The overall safety profile observed in patients with UC was generally consistent with that observed in patients with RA. Overall, the safety profile observed in patients with CD treated with RINVOQ was consistent with the known safety profile for RINVOQ.

Overall, the safety profile observed in patients with GCA treated with RINVOQ 15 mg was generally consistent with the known safety profile for RINVOQ.

The most common serious adverse reactions were serious infections.

The safety profile of RINVOQ with long-term treatment was generally similar to the safety profile during the placebo-controlled period across indications.

This is not a complete summary of all safety information.

See RINVOQ full Summary of Product Characteristics (SmPC) at www.ema.europa.eu.

Globally, prescribing information varies; refer to the individual country product label for complete information.

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of actions and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 19 immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References

AbbVie. Data on file ABVRRTI81580. AbbVie. Data on file ABVRRTI81456. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010;62(2):177-188, quiz 189-190. Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3(1):17011 Davey L, Clarke V, Jenkinson E. Living with alopecia areata: an online qualitative survey study. Br J Dermatol. 2019;180(6):1377-1389 Bain KA, McDonald E, Moffat F, et al. Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. Br J Dermatol. 2020;182(1):130-137 RINVOQ [Package Insert]. North Chicago, IL: AbbVie Inc.; 2026 SOURCE AbbVie